dc.contributor.author | Sando, Sigrid Botne | |
dc.contributor.author | Albrektsen, Grethe | |
dc.contributor.author | Møller, Ina | |
dc.contributor.author | White, Linda | |
dc.contributor.author | Berge, Guro | |
dc.contributor.author | Grøntvedt, Gøril Rolfseng | |
dc.contributor.author | Lauridsen, Camilla | |
dc.contributor.author | Bråthen, Geir | |
dc.date.accessioned | 2017-03-17T11:29:28Z | |
dc.date.available | 2017-03-17T11:29:28Z | |
dc.date.created | 2016-10-14T10:43:04Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 1471-2377 | |
dc.identifier.uri | http://hdl.handle.net/11250/2434511 | |
dc.description.abstract | Background
α-Synuclein has been proposed as a potential biomarker for Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). However, results from α-synuclein measurements in cerebrospinal fluid (CSF) have been inconclusive, and to our knowledge, longitudinal studies of changes prior to the AD diagnosis have not been investigated.
Methods
Levels of α-synuclein at baseline and after one and two years were measured in CSF, by enzyme-linked immunosorbent assay. Twenty-six patients with early AD (AD-AD), 48 patients with aMCI, subdivided as 23 that developed AD during follow-up (MCI-AD), and 25 that did not (MCI-MCI), and 25 healthy control individuals, were included. One-way ANOVA was applied to compare mean α-synuclein baseline values between all four study groups, and a linear mixed model was used to compare mean change over time between the three patient groups. Linear associations between α-synuclein and amyloid-β 1–42 (Aβ42), amyloid-β 1–40 (Aβ40), total tau and phosphorylated tau were also examined.
Results
A large variation in individual α-synuclein CSF levels was observed, particularly in the MCI-AD group. No significant differences were found in mean α-synuclein levels between all the study groups at baseline. When using a linear mixed model, no significant differences were found at follow-up for estimated mean changes between the patient groups. MCI-AD patients with short duration of symptoms prior to inclusion in the study (≤2 years) had considerably higher mean CSF α-synuclein levels compared to patients with a longer symptom duration (802.2 vs. 442.8 pg/mL, p = 0.01). No such difference was seen in the MCI-MCI or AD-AD groups. Significant linear associations (p < 0.0005) between α-synuclein and Aβ40, total tau and phosphorylated tau were found.
Conclusion
The observed difference in mean CSF α-synuclein level according to duration of symptoms in the MCI-AD group, may be an indication of changes related to disease progression. However, the lack of significant differences between groups, as well as the large individual variation in CSF levels of α-synuclein in the present study, suggest that α-synuclein is not a useful biomarker for AD. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | BioMed Central | nb_NO |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.source.volume | 16 | nb_NO |
dc.source.journal | BMC Neurology | nb_NO |
dc.source.issue | 180 | nb_NO |
dc.identifier.doi | 10.1186/s12883-016-0706-0 | |
dc.identifier.cristin | 1391680 | |
dc.description.localcode | © 2016 The Author(s).Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, andreproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link tothe Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | nb_NO |
cristin.unitcode | 194,65,30,0 | |
cristin.unitcode | 194,65,1,0 | |
cristin.unitname | Institutt for nevromedisin | |
cristin.unitname | DMF fakultetsadministrasjon | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |